Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: taxol and vindesine
- 26 July 2003
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 66 (5) , 739-748
- https://doi.org/10.1016/s0006-2952(03)00400-3
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Pharmacology and Therapeutic Applications of A3 Receptor SubtypeCurrent Topics in Medicinal Chemistry, 2003
- Metastatic melanoma: ChemotherapySeminars in Oncology, 2002
- Adenosine Receptors as Mediators of Both Cell Proliferation and Cell Death of Cultured Human Melanoma CellsJournal of Investigative Dermatology, 2002
- Adenosine- and Adenine-Nucleotide-Mediated Inhibition of Normal and Transformed Keratinocyte Proliferation is Dependent upon Dipyridamole-Sensitive Adenosine TransportJournal of Investigative Dermatology, 2000
- A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanomaCancer, 2000
- Paclitaxel and tamoxifenCancer, 2000
- Differential effect of adenosine on tumor and normal cell growth: Focus on the A3 adenosine receptorJournal of Cellular Physiology, 2000
- Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cellsInternational Journal of Cancer, 1998
- Adenosine A3Receptor Agonists Protect HL-60 and U-937 Cells from Apoptosis Induced by A3AntagonistsBiochemical and Biophysical Research Communications, 1997
- Induction of Apoptosis in HL-60 Human Promyelocytic Leukemia Cells by Adenosine A3Receptor AgonistsBiochemical and Biophysical Research Communications, 1996